We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis
Authors
Roberts, Zachary J.Goutagny, Nadege
Perera, Pin-Yu
Kato, Hiroki
Kumar, Himanshu
Kawai, Taro
Akira, Shizuo
Savan, Ram
van Echo, David
Fitzgerald, Katherine A
Young, Howard A.
Ching, Lai-Ming
Vogel, Stefanie N.
UMass Chan Affiliations
Department of Medicine, Division of Infectious Diseases and ImmunologyDocument Type
Journal ArticlePublication Date
2007-06-15Keywords
AnimalsAntineoplastic Agents
Cells, Cultured
Cytokines
DNA
Enhancer Elements, Genetic
Female
Gene Expression Regulation
Immunoglobulin Light Chains
Interferon Regulatory Factor-3
Macrophages, Peritoneal
Mice
Mice, Inbred C57BL
Polymerase Chain Reaction
Protein Kinases
Protein-Serine-Threonine Kinases
Signal Transduction
Xanthones
Immunology and Infectious Disease
Metadata
Show full item recordAbstract
Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)-interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway. DMXAA treatment of primary mouse macrophages resulted in robust IRF-3 activation and approximately 750-fold increase in IFN-beta mRNA, and in contrast to the potent Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal nuclear factor kappaB-dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3 but was myeloid differentiation factor 88-, Toll-interleukin 1 receptor domain-containing adaptor inducing IFN-beta-, IFN promoter-stimulator 1-, and inhibitor of kappaB kinase-independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of mouse macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-beta expression were inhibited by salicylic acid. These findings detail a novel pathway for TBK1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs.Source
J Exp Med. 2007 Jul 9;204(7):1559-69. Epub 2007 Jun 11. Link to article on publisher's siteDOI
10.1084/jem.20061845Permanent Link to this Item
http://hdl.handle.net/20.500.14038/35245PubMed ID
17562815Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1084/jem.20061845